EUSA Pharma’s dinutuximab beta has gained European approval for its immunotherapy for children affected by a rare and devastating form of cancer, a move which exploits a gap in the market left ...

The cost-effectiveness body said in first draft guidance that evidence suggests Qarziba (dinutuximab beta) could increase overall survival compared with standard treatment, but there is ...